Petrolheads often spend hours on end poring over the latest models from their favorite manufacturers. As much fun as it is salivating over their specs and considering the virtues of different ...

Systemic lupus erythematosus (SLE) is the most common type of lupus, a chronic autoimmune disease. Symptoms include fatigue, joint pain, and rashes across your nose and cheeks. While there’s no ...

Not all of these writers might be considered “Western,” yet each of them are featured on this quarter’s syllabus for Stanford’s Structured Liberal Education (SLE) program. This reflects a ...

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

VIENNA — Glucocorticoid discontinuation is possible without increasing flare risk, if tapered slowly and carefully, in patients with systemic lupus erythematosus (SLE) in stable remission.

ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus nephritis (LN), and SLE with extrarenal involvement. The Company is ...

Aerobic capacity and cardiovascular risk both improve when people with systemic lupus erythematosus (SLE) exercise regularly, according to a new systematic review. About two-thirds of people with ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...